Clinical Manifestations, Treatment and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Single-Center Experience from Iran

Document Type : Original Article

Authors
Farzad Ferdosian 1 , 2
Mohammad Emad Sharifi 3 , 4
Mehran Karimi 1 , 2
Naeimeh Naserzadeh 1 , 2
Zahra Nafei 1 , 2
Niloufar Vaziri Bozorg 5
Shekoofeh Savabieh 2 , 4
1 Children Growth Disorder Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 Department of Pediatrics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
4 Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
5 School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
10.18502/wjpn.v8i2.22107
Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C) is a documented complication arising from SARS-CoV-2 infection. Even pediatric patients who present with mild initial COVID-19 symptoms may subsequently experience severe morbidity or mortality due to MIS-C; therefore, early identification and prompt clinical management are essential for achieving favorable outcomes. This study aimed to assess the clinical characteristics, therapeutic strategies, and patient outcomes among children diagnosed with MIS-C in Yazd, Iran.
Methods: This study included all pediatric patients admitted to Shahid Sadoughi Hospital in Yazd, Iran, who presented with either suspected or confirmed MIS-C between March 2020 and March 2021. Comprehensive data were extracted from medical records, including demographics, clinical symptoms, laboratory biomarkers, imaging results, and treatment modalities.
Results: The study included 40 children (52.5% males, 47.5% females, median age 7.3 years). Fever was the predominant symptom (87.5%), followed by gastrointestinal complaints (57.5%) and mucocutaneous abnormalities (20%). The digestive, respiratory, and neurological systems were most frequently involved. Hospitalisation lasted 1–7 days in 75% and 8–14 days in 22.5% of patients. Disease severity was severe in 25%, moderate in 47.5%, and mild in 27.5%. Remdesivir (40%), corticosteroids (52.5%), and intravenous immunoglobulin (47.5%) were used as treatment. Notably, the overall mortality rate was 22.5% (9/40), substantially higher than the rates reported in most international studies. Conclusion: This elevated mortality underscores the urgent need for enhanced early detection, rapid referral systems, and timely immunomodulatory therapy. Previous studies have reported that COVID-19 vaccination is associated with a reduced incidence of MIS-C. 
Keywords
Multisystem inflammatory syndrome in children (MIS-C)
COVID-19
SARS-CoV-2
Pediatrics
Mortality
Iran
1. Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis. Pediatr Pulmonol. 2021;56(5):837-48.
2. Patel JM. Multisystem Inflammatory Syndrome in Children (MIS-C). Curr Allergy Asthma Rep. 2022;22(5):53-60.
3. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-46.
4. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607-8.
5. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-8.
6. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-81.e7.
7. Modarresi SZ, Savabieh S, Naserzadeh N, Yazdanparast M, Talaeipour S. Multisystem Inflammatory Syndrome in Children (MIS-C): A Review of Short- and Long-Term Complications. Iran J Ped Hematol Oncol. 2026;16(1):788-805
8. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022;74(4):e1-e20.
9. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr Infect Dis J. 2020;39(11):e340-e6.
10. World Health O. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Geneva: World Health Organization; 2020.
11. Centers for Disease C, Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Atlanta: Centers for Disease Control and Prevention; 2020.
12. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation 2020; 142(5): 429-36.
13. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020; 324(3): 259-69.          14. Shyong O, Alfakhri N, Bates SV, Carroll RW, Gallagher K, Huang L, et al. Multisystem Inflammatory Syndrome in Children: A Comprehensive Review Over the Past Five Years. J Intensive Care Med. 2025: 8850666251320558.
15. Tang Y, Li W, Baskota M, Zhou Q, Fu Z, Luo Z, et al. Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: a systematic review of published case studies. Transl Pediatr 2021; 10(1): 121-35.
16. Guimarães D, Pissarra R, Reis-Melo A, Guimarães H. Multisystem inflammatory syndrome in children (MISC): A systematic review. Int J Clin Pract 2021; 75(11): e14450.
17. Kamfar S, Zeinali V, Alaei F, Farahbakhsh N, Tabatabaee S, Mosallanejad A. COVID-19 Related Multi-System Inflammatory Syndrome in Children (MIS-C): A Systematic Review. Archives of Pediatric Infectious Diseases 2024; 12(3): e139928.
18. Rabinowicz S, Leshem E, Pessach IM. COVID-19 in the Pediatric Population-Review and Current Evidence. Curr Infect Dis Rep 2020; 22(11): 29.
19. Seijbel TC, Hoste L, Buysse CMP, Dulfer K, Haerynck F, de Hoog M, Ketharanathan N. Multidimensional 1-Year Outcomes After Intensive Care Admission for Multisystem Inflammatory Syndrome in Children. Crit Care Explor 2025; 7(1): e1213.
20. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020;174(9):868-73.
21. Albanji MH, Baghafar AA, Alghanmi YA, Shaaban MM, Alkashlan EA, Sende HH, et al. Clinical Presentation and Management of Multisystem Inflammatory Syndrome in Children With COVID-19: A Systematic Review. Cureus 2023; 15(10): e46918.
22. Lampidi S, Maritsi D, Charakida M, Eleftheriou I, Farmaki E, Spyridis N, et al. Multisystem inflammatory syndrome in children (MIS-C): A nationwide collaborative study in the Greek population. Eur J Pediatr 2024; 183(4): 1693-702.
23. Henderson LA. COVID-19-Related Multi-systemic Inflammatory Syndrome in Children (MIS-C). Adv Exp Med Biol 2024; 1448: 409-25.
24. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med 2021; 385(1): 23-34.
25. McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med 2021; 385(1): 11-22.
26. Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA 2021; 325(9): 855-64.
27. Al Rawahi H, Al Ismaili R, Al Zeidi A, Al Farsi A, Al Waili B, Al Noobi B, et al. Multisystem Inflammatory Syndrome in Children: A Multicenter Retrospective Study. Dr Sulaiman Al Habib Medical Journal 2024; 6(2): 58-65.
28. Rostami-Maskopaee F, Ladomenou F, Razavi-Amoli SK, Navaeifar MR, Hajialibeig A, Shahbaznejad L, et al. Clinical characteristics and outcomes of the multisystem inflammatory syndrome in children (MIS-C) following COVID-19 infection in Iran: A multicenter study. PLoS One 2022; 17(9): e0274104.
29. Armin S, Fahimzad SA, Rafiei Tabatabaei S, Mansour Ghanaiee R, Marhamati N, Ahmadizadeh SN, et al. COVID-19 Mortality in Children: A Referral Center Experience from Iran (Mofid Children's Hospital, Tehran, Iran). Can J Infect Dis Med Microbiol 2022; 2022: 2737719.
30. Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health 2021; 5(5): 323-31.
31. Jonat B, Gorelik M, Boneparth A, Geneslaw AS, Zachariah P, Shah A, et al. Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children's Hospital in New York City: Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow-Up. Pediatr Crit Care Med 2021; 22(3): e178-e91.
32. Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 2020; 395(10239): 1741-3.
33. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol 2020; 20(8): 453-4.
34. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69(32): 1074-80.
35. Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69(40): 1450-6.
36. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e99.
37. Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y. Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018. J Pediatr 2020; 225: 23-9.e2.
38. Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases. Gastroenterology. 2020;159(4):1571-4.e2.
39. Ramcharan T, Nolan O, Lai CY, Prabhu N, Krishnamurthy R, Richter AG, et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020;41(7):1391-401.
40. Matsubara D, Kauffman HL, Wang Y, Calderon-Anyosa R, Nadaraj S, Elias MD, et al.
Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States. J Am Coll Cardiol 2020; 76(17): 1947-61.
41. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA 2021; 325(11): 1074-87.
42. Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, et al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Circulation 2021; 143(1): 21-32.
43. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr 2020; 174(9): 882-9.
44. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; 4(9): 653-61.
45. Schupper AJ, Yaeger KA, Morgenstern PF. Neurological manifestations of pediatric multi-system inflammatory syndrome potentially associated with COVID-19. Childs Nerv Syst 2020; 36(8): 1579-80.
46. LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, et al. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol 2021; 78(5): 536-47.
47. American Academy of P. Multisystem inflammatory syndrome in children (MIS-C) interim guidance. Itasca: American Academy of Pediatrics; 2021.
48. Royal College of P, Child H. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians. London: Royal College of Paediatrics and Child Health; 2021.                                                49. Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study. Lancet Reg Health Eur 2022; 17: 100393.
50. Penner J, Abdel-Mannan O, Grant K, Maillard S, Kucera F, Hassell J, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health. 2021; 5(7): 473-82.
51. Belot A, Antona D, Renolleau S, Javouhey E, Hentgen V, Angoulvant F, et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill. 2020; 25(22).
52. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020; 79(8): 999-1006.
53. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383(19): 1827-37.
54. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020; 324(11): 1048-57.
55. Bhumbra S, Malin S, Kirkpatrick L, Khaitan A, John CC, Rowan CM, Enane LA. Clinical Features of Critical Coronavirus Disease 2019 in Children. Pediatr Crit Care Med. 2020; 21(10): e948-e53.
56. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. J Pediatr 2020; 223: 199-203.e1.
57. Brumfiel CM, DiLorenzo AM, Petronic-Rosic VM. Dermatologic manifestations of COVID-19-associated multisystem inflammatory syndrome in children. Clin Dermatol 2021; 39(2): 329-33.
58. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020; 370: m3249.
59. Kapoor R, Chandra T, Singh CP, Singh R, Pandey I. Multisystem Inflammatory Syndrome in Children (MIS-C) Related to SARS-CoV-2 and 1-Year Follow-up. Indian J Pediatr 2023; 90(10): 1008-12.
60. Pawar R, Gavade V, Patil N, Mali V, Girwalkar A, Tarkasband V, et al. Neonatal Multisystem Inflammatory Syndrome (MIS-N) Associated with Prenatal Maternal SARS-CoV-2: A Case Series. Children (Basel). 2021; 8(7): 572.
61. Bustos BR, Jaramillo-Bustamante JC, Vasquez-Hoyos P, Cruces P, Díaz F. Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2: A Case Series Quantitative Systematic Review. Pediatr Emerg Care 2021; 37(1): 44-7.
62. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, Gupta A. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev 2021; 38: 51-7.
63. Elias MD, McCrindle BW, Larios G, Choueiter NF, Dahdah N, Harahsheh AS, et al. Management of Multisystem Inflammatory Syndrome in Children Associated With COVID-19: A Survey From the International Kawasaki Disease Registry. CJC Open 2020; 2(6): 632-40.
64. Harthan AA, Nadiger M, McGarvey JS, Hanson K, Gharpure VP, Bjornstad EC, et al. Early combination therapy with immunoglobulin and steroids is associated with shorter ICU length of stay in Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19: A retrospective cohort analysis from 28 U.S. Hospitals. Pharmacotherapy 2022; 42(7): 529-39.
65. Schlapbach LJ, Andre MC, Grazioli S, Schöbi N, Ritz N, Aebi C, et al. Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland. Frontiers in Pediatrics. 2021;Volume 9 - 2021.
66. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, Valentini P. Preliminary evidence on long COVID in children. Acta Paediatr 2021; 110(7): 2208-11.
67. Batu ED, Demirkan FG, Sag E, Lamot L, Faleye A, Marrani E, et al. The impact of the COVID-19 pandemic on pediatric rheumatology practice: an international, cross-sectional survey study. Semin Arthritis Rheum 2023; 63: 152289.
68. Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, Montin D. SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children. Pediatrics 2020; 146(2): e20201711.
69. Koné-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open 2020; 6(2): e001333.
70. Grimaud M, Starck J, Levy M, Marais C, Chareyre J, Khraiche D, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care 2020; 10(1): 69.
71. Kompaniyets L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, et al. Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children. JAMA Netw Open 2021; 4(6): e2111182.
72. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. JAMA Pediatr. 2020;174(10):e202430.
73. Preston LE, Chevinsky JR, Kompaniyets L, Lavery AM, Kimball A, Boehmer TK, Goodman AB. Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19. JAMA Netw Open 2021; 4(4): e215298.
74. Moreira A, Chorath K, Rajasekaran K, Burmeister F, Ahmed M, Moreira A. Demographic predictors of hospitalization and mortality in US children with COVID-19. Eur J Pediatr. 2021; 180(5): 1659-63.
75. Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, et al. Risk Factors for Severe
COVID-19 in Children. Pediatr Infect Dis J 2021; 40(4): e137-e45.
76. Hameed S, Elbaaly H, Reid CEL, Santos RMF, Shivamurthy V, Wong J, Jogeesvaran KH. Spectrum of Imaging Findings at Chest Radiography, US, CT, and MRI in Multisystem Inflammatory Syndrome in Children Associated with COVID-19. Radiology 2021; 298(1): E1-e10.
77. Jain S, Sen S, Lakshmivenkateshiah S, Bobhate P, Venkatesh S, Udani S, et al. Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India. Indian Pediatr 2020; 57(11): 1015-9.
78. Shah SS, Naidu PKK, Selvam S, Shetty R, Bhat CS, Maheshwari S. Cardiac findings in multisystem inflammatory syndrome in children: Short term follow up in a large Indian series. Ann Pediatr Cardiol. 2023;16(2):94-101.
79. Shahbaznejad L, Navaeifar MR, Abbaskhanian A, Hosseinzadeh F, Rahimzadeh G, Rezai MS. Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran. BMC Pediatr 2020; 20(1): 513.
80. Hoseininasab A, Sinaei R, Bagheri MM, Ahmadipour M, Derakhshan R, Najafzadeh MJ, et al. Multisystem inflammatory syndrome in children (MIS-C) post-COVID-19 in Iran: clinical profile, cardiac features, and outcomes. BMC Pediatrics 2024; 24(1): 179.
81. Vafaee Shahi M, Vahedi Z, Behmadi R, Yousefzadegan S, Mousavi A, Mahdvnia S, Mahmoudabadi R. Clinical Characteristics, Treatment, and Outcomes of Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A Single-Center Study from Iran. Journal of Comprehensive Pediatrics 2025; 16: e161545.
82. Levin M. Childhood Multisystem Inflammatory Syndrome - A New Challenge in the Pandemic. N Engl J Med 2020; 383(4): 393-5.
83. Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol 2020; 57(17): 101232.
84. Riollano-Cruz M, Akkoyun E, Briceno-Brito E, Kowalsky S, Reed J, Posada R, et al. Multisystem inflammatory syndrome in children related to COVID-19: A New York City experience. J Med Virol 2021; 93(1): 424-33.
85. García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramírez J, Slöcker Barrio M, Leóz Gordillo I, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care 2020; 24(1): 666.
86. Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health 2021; 5(2): 133-41.
87. Dove ML, Jaggi P, Kelleman M, Abuali M, Ang JY, Ballan W, et al. Multisystem Inflammatory Syndrome in Children: Survey of Protocols for Early Hospital Evaluation and Management. J Pediatr 2021; 229: 33-40.
88. Whitworth H, Sartain SE, Kumar R, Armstrong K, Ballester L, Betensky M, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood 2021; 138(2): 190-8.
89. Gaitonde M, Ziebell D, Kelleman MS, Cox DE, Lipinski J, Border WL, Sachdeva R. COVID-19-Related Multisystem Inflammatory Syndrome in Children Affects Left Ventricular
Function and Global Strain Compared with Kawasaki Disease. J Am Soc Echocardiogr 2020; 33(10): 1285-7.
90. Levy M, Recher M, Hubert H, Javouhey E, Fléchelles O, Leteurtre S, Angoulvant F. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA 2022; 327(3): 281-3.
91. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep 2022; 71(2): 52-8.
92. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health 2022; 6(5): 303-12.
93. Nygaard U, Holm M, Bohnstedt C, Chai Q, Schmidt LS, Hartling UB, et al. Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J 2022; 41(1): e25-e8.
Journal of Integrated Maternal and Pediatric Care
Volume 8, Issue 2
June 2026
Pages 108-124

  • Receive Date 22 July 2026